Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Public ClinicalTrials.gov record NCT01763905. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Double-blind, Randomized, Multicenter Study to Evaluate Safety and Efficacy of AMG 145, Compared With Ezetimibe, in Hypercholesterolemic Subjects Unable to Tolerate an Effective Dose of a HMG-CoA Reductase Inhibitor
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective was to evaluate the effect of 12 weeks of subcutaneous (SC) evolocumab every 2 weeks (Q2W) and monthly (QM), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemic adults unable to tolerate an effective dose of a statin (HMG-CoA (5-hydroxy-3-methylglutaryl-coenzyme A) reductase inhibitors).
Study identification
- NCT ID
- NCT01763905
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 307 participants
Conditions and interventions
Conditions
Interventions
- Evolocumab Biological
- Placebo to Evolocumab Drug
- Ezetimibe Drug
- Placebo to Ezetimibe Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 24, 2013 (Actual)
- Primary completion
- Nov 19, 2013 (Actual)
- Completion
- Nov 19, 2013 (Actual)
- Last update posted
- Jul 20, 2020
2013
United States locations
- U.S. sites
- 20
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Carmichael | California | 95608 | — |
| Research Site | Los Angeles | California | 90048 | — |
| Research Site | Mission Viejo | California | 92691 | — |
| Research Site | Thousand Oaks | California | 91360 | — |
| Research Site | Atlanta | Georgia | 30338 | — |
| Research Site | Atlanta | Georgia | 30342 | — |
| Research Site | Savannah | Georgia | 31406 | — |
| Research Site | Auburn | Maine | 04210 | — |
| Research Site | Traverse City | Michigan | 49684 | — |
| Research Site | St Louis | Missouri | 63110 | — |
| Research Site | Henderson | Nevada | 89052 | — |
| Research Site | Las Vegas | Nevada | 89117 | — |
| Research Site | Las Vegas | Nevada | 89148 | — |
| Research Site | New York | New York | 10029 | — |
| Research Site | Raleigh | North Carolina | 27609 | — |
| Research Site | Akron | Ohio | 44311 | — |
| Research Site | Cincinnati | Ohio | 45212 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Norman | Oklahoma | 73069 | — |
| Research Site | Houston | Texas | 77030 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 38 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01763905, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 20, 2020 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01763905 live on ClinicalTrials.gov.